Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 17 clinical trials
Infigratinib in Recurrent Glioblastoma Patients

This trial is an open-label, multicenter, Phase 0 trial that will enroll up to 20 participants with recurrent high-grade glioma with FGFR1 K656E or FGFR3 K650E mutation or FGFR3-TACC3 translocation which are scheduled for resection. In the lead-in cohort, a total of 20 participants will be enrolled into the proposed …

serum calcium
glioblastoma multiforme
hair thinning
contrast-enhanced magnetic resonance imaging
recurrent malignant glioma
  • 0 views
  • 19 Feb, 2024
Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma

Background Glioblastoma is a type of brain cancer. Treatments include radiation, chemotherapy, and surgery. But survival rates are poor. Researchers think that the drug selinexor, when combined with chemotherapy and radiation, might help.

glioblastoma multiforme
therapeutic agents
brain tumor
platelet count
ct scan
  • 0 views
  • 19 Feb, 2024
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors

This trial studies whether a customized video intervention can help to reduce anxiety in brain cancer patients undergoing radiation treatment and their caregivers. A customized neuro-imaging referenced symptom video that describes symptoms and side effects specific to the patients' tumor may result in an early and sustained reduction in anxiety …

glioblastoma multiforme
MRI
brain tumor
anxiety
psychiatric symptoms
  • 0 views
  • 19 Feb, 2024
Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma

This is a phase II open-label study investigating the efficacy, safety and pharmacokinetic(PK) properties of OKN-007 combined with temozolomide(TMZ) in patients with recurrent glioblastoma(GBM). All patients will have been previously treated with the standard-of-care treatment which includes surgical resection, radiation and chemotherapy, and in some cases treatment for recurrent disease.

  • 0 views
  • 19 Feb, 2024
Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-na ve GBM Patients.

A multi-center, open-label, single-arm, phase I/II clinical study is designed to test the safety and immunogenicity of an investigational Dendritic and Glioma Cells Fusion vaccine given with IL-12 for treatment-nave patients after resection of glioblastoma.

ejection fraction
glioblastoma multiforme
glioma
blood cell count
temozolomide
  • 0 views
  • 19 Feb, 2024
Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MPP2+ Recurrent or Progressive Glioblastoma

This phase I trial studies the side effects and best dose of chimeric antigen receptor (CAR) T cells with a chlorotoxin tumor-targeting domain in treating patients with MPP2+ glioblastoma that has come back (recurrent) or that is growing, spreading, or getting worse (progressive). Vaccines made from a gene-modified virus may …

glioblastoma multiforme
malignant glioma
leukapheresis
serum pregnancy test
neutrophil count
  • 0 views
  • 19 Feb, 2024
Cerebral Morbidity After Radiation Therapy for Brain Tumors

This study will assess cognitive function in patients with a primary brain tumour treated with radiation therapy (RT) to generate radio-sensitivity and volume effect parameters for the development of cognitive dysfunction. All types of brain tumours apart from glioblastoma will be included.

sarcomas
glioblastoma multiforme
cognitive dysfunction
brain tumor
glioblastoma
  • 0 views
  • 19 Feb, 2024